CD8A and neoplasm: Since only NKT cells, but not other immune cells, activate NK and CD8 killer T cells at the same time, thus eliminating both MHC positive and negative tumor cells, the NKT cell-targeted therapy is a promising strategy for cancer treatment (Figures 1B,C).